Latest Development Pipeline News

Minerals 260 has agreed to sell its Aston Lithium-REE Project to Delta Lithium for $450,000 cash plus a 1.5% royalty, redirecting its efforts toward advancing the 2.3 million ounce Bullabulling Gold Project in Western Australia.

Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.

Astute Metals has reported its highest-grade lithium intercept to date at the Red Mountain Project in Nevada, extending mineralisation over a 5.6-kilometre strike length and reinforcing the project's growing significance in the US lithium landscape.

Elementos Limited has locked in a $5 million strategic placement from Australia’s largest tin producer, Metals X, to accelerate development of its key tin projects in Spain and Tasmania.

Hot Chili Limited has announced a significant expansion of its La Verde copper-gold porphyry discovery in Chile, doubling the known mineralisation footprint and confirming multiple higher-grade zones. The discovery remains open for further growth with phase-two drilling planned.

Lendlease has partnered with The Crown Estate to create a 50/50 joint venture aimed at accelerating capital recycling of over $300 million through UK commercial and residential developments. The deal also includes a $1.2 billion Australian office investment mandate, boosting Lendlease’s funds under management to $20 billion.

Contact Energy Limited has announced a court-approved scheme to acquire Manawa Energy Limited, offering Manawa shareholders $1.12 cash plus 0.5830 new Contact shares per share, representing a significant premium. The merger aims to create a diversified renewable energy portfolio with substantial synergies and growth prospects.

Aspen Group has launched a $74 million equity raising to reduce debt and capitalize on growth opportunities in affordable housing, maintaining its FY25 earnings guidance.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Lendlease is in advanced talks to form a 50/50 joint venture with Crown Estate, aiming to accelerate capital release and enhance development delivery across its UK portfolio.

Unibail-Rodamco-Westfield unveils a confident 2025-28 strategy targeting robust EBITDA growth, expanding retail media, and increased shareholder returns. The plan balances disciplined capital allocation with ambitious development and licensing initiatives.

PEXA Group’s third-quarter results align with expectations, driven by Australian growth and UK market headwinds. The company reaffirms its FY25 guidance while navigating ongoing business assessments and regulatory milestones.